
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is a strong investment opportunity due to its diverse portfolio of key products in highly profitable sectors such as cancer, cardiometabolic diseases, and immunology. This, combined with the company's projected revenue and EPS growth, as well as its strong financial position, make it a promising stock for long-term investors. Additionally, potential risks such as slowing growth, negative clinical data, and industry headwinds can be mitigated by the company's solid research and development efforts and strategic acquisitions.
Bears say
Eli Lilly is reporting excellent sales and a positive outlook for their range of drugs, but a closer look into their products reveals concerns about safety and the effectiveness of their newly launched drug, Foundayo. While their earnings and revenue projections continue to be strong, the negative impact of any potential safety issues can't be ignored - leading to a negative outlook on the stock. Additionally, while the company is making progress with their new drug launch, it still lags behind its competitor, Oral Wegovy, making it difficult to see significant growth in the near term.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares